JP2024059648A5 - - Google Patents

Download PDF

Info

Publication number
JP2024059648A5
JP2024059648A5 JP2024014560A JP2024014560A JP2024059648A5 JP 2024059648 A5 JP2024059648 A5 JP 2024059648A5 JP 2024014560 A JP2024014560 A JP 2024014560A JP 2024014560 A JP2024014560 A JP 2024014560A JP 2024059648 A5 JP2024059648 A5 JP 2024059648A5
Authority
JP
Japan
Prior art keywords
drawings
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024014560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024059648A (ja
JP7760626B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2020/037054 external-priority patent/WO2020252066A1/en
Application filed filed Critical
Publication of JP2024059648A publication Critical patent/JP2024059648A/ja
Publication of JP2024059648A5 publication Critical patent/JP2024059648A5/ja
Application granted granted Critical
Publication of JP7760626B2 publication Critical patent/JP7760626B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024014560A 2019-06-11 2024-02-02 治療に使用するための抗ソルチリン抗体 Active JP7760626B2 (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962860207P 2019-06-11 2019-06-11
US62/860,207 2019-06-11
US201962868850P 2019-06-28 2019-06-28
US62/868,850 2019-06-28
US201962874475P 2019-07-15 2019-07-15
US62/874,475 2019-07-15
US201962947503P 2019-12-12 2019-12-12
US62/947,503 2019-12-12
US202062961591P 2020-01-15 2020-01-15
US62/961,591 2020-01-15
PCT/US2020/037054 WO2020252066A1 (en) 2019-06-11 2020-06-10 Anti-sortilin antibodies for use in therapy
JP2021573616A JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021573616A Division JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体

Publications (3)

Publication Number Publication Date
JP2024059648A JP2024059648A (ja) 2024-05-01
JP2024059648A5 true JP2024059648A5 (cg-RX-API-DMAC7.html) 2025-02-28
JP7760626B2 JP7760626B2 (ja) 2025-10-27

Family

ID=71948712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573616A Active JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体
JP2024014560A Active JP7760626B2 (ja) 2019-06-11 2024-02-02 治療に使用するための抗ソルチリン抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021573616A Active JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体

Country Status (11)

Country Link
US (2) US20200392229A1 (cg-RX-API-DMAC7.html)
EP (1) EP3983441A1 (cg-RX-API-DMAC7.html)
JP (2) JP7512310B2 (cg-RX-API-DMAC7.html)
KR (1) KR102919581B1 (cg-RX-API-DMAC7.html)
CN (1) CN114423450B (cg-RX-API-DMAC7.html)
AU (1) AU2020291527A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025077A2 (cg-RX-API-DMAC7.html)
IL (1) IL288728A (cg-RX-API-DMAC7.html)
MX (1) MX2021015212A (cg-RX-API-DMAC7.html)
TW (1) TWI877170B (cg-RX-API-DMAC7.html)
WO (1) WO2020252066A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
SMT202300110T1 (it) 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso
JP2023553399A (ja) * 2020-12-02 2023-12-21 アレクトル エルエルシー 抗ソルチリン抗体の使用法
JP2024526060A (ja) * 2021-06-08 2024-07-17 アレクトル エルエルシー 抗ソルチリン抗体の使用方法
US20250345446A1 (en) 2022-06-23 2025-11-13 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
EP3991748A3 (en) * 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
AU2018255489B2 (en) 2017-04-21 2024-06-13 Implicit Bioscience Limited CD 14 antagonist antibodies for treating neurodegenerative diseases
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
SMT202300110T1 (it) * 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso

Similar Documents

Publication Publication Date Title
JP2022191211A5 (cg-RX-API-DMAC7.html)
JP2020127044A5 (cg-RX-API-DMAC7.html)
JP2025138632A5 (cg-RX-API-DMAC7.html)
JP2024023385A5 (cg-RX-API-DMAC7.html)
JP2024059739A5 (cg-RX-API-DMAC7.html)
JP2022068302A5 (cg-RX-API-DMAC7.html)
JP2025138641A5 (cg-RX-API-DMAC7.html)
JP2020127428A5 (cg-RX-API-DMAC7.html)
JP2023022224A5 (cg-RX-API-DMAC7.html)
JP2022523200A5 (cg-RX-API-DMAC7.html)
JP2022538797A5 (cg-RX-API-DMAC7.html)
JP2024016014A5 (cg-RX-API-DMAC7.html)
JP2025506484A5 (cg-RX-API-DMAC7.html)
JP2024112817A5 (cg-RX-API-DMAC7.html)
JP2023085551A5 (cg-RX-API-DMAC7.html)
JP2025118629A5 (cg-RX-API-DMAC7.html)
JP2022060295A5 (cg-RX-API-DMAC7.html)
JP2023100643A5 (cg-RX-API-DMAC7.html)
JP2025084837A5 (cg-RX-API-DMAC7.html)
JP2026004279A5 (cg-RX-API-DMAC7.html)
JP2024063214A5 (cg-RX-API-DMAC7.html)
JP2023509441A5 (cg-RX-API-DMAC7.html)
JP2024534771A5 (cg-RX-API-DMAC7.html)
JP2024170456A5 (cg-RX-API-DMAC7.html)
JP2023011759A5 (cg-RX-API-DMAC7.html)